Aspartate aminotransferase-immunoglobulin complexes in patients with chronic liver disease

Table 1 Clinical findings of 128 patients with liver disease.

	Number of cases	Sex (M:F)	Mean of age (yr)	Positive rate of HBsAg, n (%)	Positive rate of anti-HCV, n (%)
Alcoholic liver injury	6	5:01	57±6	0	0
Chronic hepatitis	67	45:22:00	52±13	11 (16.4)	49 (73.1)
Liver cirrhosis	45	29:16:00	56±10	8 (17.8)	26 (57.8)
Hepatocellular carcinoma	10	9:1	66±7	3 (30.0)	5 (50.0)

Table 2 Comparison of clinical findings between the patients with and without AST-IgA complex in serum.

	AST-IgA complex in serum		P
	(-)	(+)
Number of cases	59	69
Sex (M:F)	40:19:00	48:21:00	NS
Mean of age (yr)	52±13	58±12	<0.01
Number of patients with positive HBsAg	12	10	NS
Number of patients with positive anti-HCV	33	47	NS
Number of patients with liver cirrhosis	18	37	<0.02

Table 3 Comparison of laboratory findings between the patients with and without AST–IgA complexes in serum (mean±SD).

	AST-IgA complex in serum		P
	(-)	(+)
g globulin (%)	21.0±5.8	24.5±6.5	<0.01
AST (IU/L)	55±25	115±50	<0.001
AST/ALT	1.16±0.56	1.37±0.61	<0.05
ChE (△pH)	0.79±0.25	0.61±0.27	<0.001
IgG (mg/dL)	1980±568	2211±532	NS
IgA (mg/dL)	299±150	397±195	<0.01
IgM (mg/dL)	178±114	195±101	NS